These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 16225469)

  • 21. Fatty liver: a novel component of the metabolic syndrome.
    Kotronen A; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know.
    Akbar DH; Kawther AH
    Med Sci Monit; 2006 Jan; 12(1):RA23-6. PubMed ID: 16369477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease.
    Adams LA; Angulo P; Lindor KD
    CMAJ; 2005 Mar; 172(7):899-905. PubMed ID: 15795412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silent non-alcoholic fatty liver disease-a clinical-histological study.
    Sorrentino P; Tarantino G; Conca P; Perrella A; Terracciano ML; Vecchione R; Gargiulo G; Gennarelli N; Lobello R
    J Hepatol; 2004 Nov; 41(5):751-7. PubMed ID: 15519647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
    Marchesini G; Natale S; Manini R; Agostini F
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():37-9. PubMed ID: 16225470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
    Oh MK; Winn J; Poordad F
    Aliment Pharmacol Ther; 2008 Sep; 28(5):503-22. PubMed ID: 18532991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
    Tsochatzis E; Papatheodoridis GV; Manesis EK; Kafiri G; Tiniakos DG; Archimandritis AJ
    Aliment Pharmacol Ther; 2008 Jan; 27(1):80-9. PubMed ID: 17919273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological assessment of non-alcoholic fatty liver disease.
    Hübscher SG
    Histopathology; 2006 Nov; 49(5):450-65. PubMed ID: 17064291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis.
    Manco M; Bedogni G; Marcellini M; Devito R; Ciampalini P; Sartorelli MR; Comparcola D; Piemonte F; Nobili V
    Gut; 2008 Sep; 57(9):1283-7. PubMed ID: 18218674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significant correlations between severe fatty liver and risk factors for metabolic syndrome.
    Hsiao PJ; Kuo KK; Shin SJ; Yang YH; Lin WY; Yang JF; Chiu CC; Chuang WL; Tsai TR; Yu ML
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2118-23. PubMed ID: 18031368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.
    Wong VW; Hui AY; Tsang SW; Chan JL; Wong GL; Chan AW; So WY; Cheng AY; Tong PC; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1215-22. PubMed ID: 17014580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease.
    Angulo P
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.
    Schindhelm RK; Diamant M; Dekker JM; Tushuizen ME; Teerlink T; Heine RJ
    Diabetes Metab Res Rev; 2006; 22(6):437-43. PubMed ID: 16832839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
    Sanyal AJ
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases.
    Powell EE; Jonsson JR; Clouston AD
    Dig Dis; 2010; 28(1):186-91. PubMed ID: 20460909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.